Breaking News, Financial News

Financial Report: Abbott 2Q

Humira sales continue to drive pharma growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott 2Q 2Q Revenues: $9.6 billion (+9%) 2Q Earnings: $1.9 billion (+50%) YTD Revenues: $18.7 billion (+13%) YTD Earnings: $2.8 billion (+22%) Comments: Growth in the quarter was driven by a 13% increase in Pharmaceutical sales. Humira sales approached $2.0 billion in the quarter, up 25%. TRILIPIX/TriCor sales were $419 million, up 6%. Kaletra sales were up 14% to $336 million. Niaspan sales were up 17% to $247 million. Lupron sales were up 9% to $205 million. Pediatric Nutritionals accoun...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters